# Nataliya Andreychuk

Nataliya Andreychuk shares perspectives on pharma marketing and content operations, including how teams can reuse approved content, improve content activation, and apply AI in their workflows. She also hosts Pharma Talks conversations with people working in pharma.

- Profile: https://b2binfluencer.marketing/creators/nataliya-andreychuk/
- LinkedIn: https://www.linkedin.com/in/andreychuk
- LinkedIn followers: 12,866
- Median of last 8 posts: 28 reactions, 1 comments (checked 2026-11-02)
- YouTube: https://www.youtube.com/channel/UCWlpXCeBtfM8GVFf6hOR1Yg
- Topics: artificial-intelligence, supply-chain, ai-in-marketing
- Based on 8 dated posts, latest 2026-10-02

## Summary

They are most useful for pharma content operations, content activation, reuse, and AI workflow discussions.

- Best for: This fits a pharma marketing technology webinar with them presenting on content supply chain activation.
- Not for: This does not fit consumer financial services short-form video promoting cashback with discount codes.
- Check first: Confirm audience demographics, sponsorship format, and past webinar attendance data.

### Takeaways

- Pharma has solved content creation but not content activation.
- Reuse is blocked by formats and weak governance, not by a shortage of content.
- Most of what marketing calls personalisation is segmentation.

## Main ideas

- **Pharma has solved content creation but not content activation**: Andreychuk argues that producing more approved assets will not produce more engagement until content, compliance and field readiness run as one loop. The first move is not a new batch of content but an honest look at what already exists, followed by matching the right asset to the right person at the moment of need.
- **Experience creates assumptions, so benchmark the data before redesigning**: Andreychuk's argument is that transformation often fails because it transforms the wrong thing. Experience is valuable but also generates assumptions, and looking at large volumes of real workflow records can make those assumptions look different. Published benchmarks and a maturity framework give teams a way to compare their own operations before redesigning them.
- **Reuse is blocked by formats and weak governance, not by a shortage of content**: Andreychuk argues that pharma has more content than it knows what to do with, yet much of it is trapped in formats that are hard to reuse. Localising or adapting a legacy document means rebuilding it. The fix is structural: break content into reusable elements while preserving the structure and meaning that make those elements valuable, and start from simple foundations rather than complex modular programmes.
- **AI raises an operating-model question, not just a speed question**: Andreychuk accepts that pharma has learned to use AI to speed work up, then argues the harder question is what has to change in roles, review steps and handoffs around it. The future commercial leader is framed as a builder, an orchestrator or an AI manager, and AI demonstrations are presented as a way to move approved messaging into channel-ready content through localisation and compliance steps.
- **Most of what marketing calls personalisation is segmentation**: Andreychuk draws a line between putting a large group of people into a segment and personalising a message to an individual, and says segmentation is not wrong until teams treat it as sufficient. The deeper failure described is internal: marketing, sales and customer success each act on a different signal while the customer experiences one brand.
- **Trust in pharma is tied to access, affordability and transparent pricing**: This argument is carried mainly by a guest conversation rather than by Andreychuk alone. The framing is a trust paradox: pharma develops life-changing medicines, but scientific breakthroughs alone do not guarantee public trust while patients still face barriers to access, affordability and understanding their treatment options.

## Work to read

- [Pharma is running a content graveyard](https://www.linkedin.com/posts/andreychuk_pharma-is-running-a-content-graveyard-numbers-activity-7510680587104309248-C1tH)
- [The most dangerous thing about transformation is transforming the wrong thing](https://www.linkedin.com/posts/andreychuk_the-most-dangerous-thing-about-transformation-activity-7511685970686185472-U0ec)
- [Do we have a content graveyard problem in pharma?](https://www.linkedin.com/posts/andreychuk_do-we-have-a-content-graveyard-problem-in-activity-7521871885257555968-ck4Y)
- [We have more pharma content than we know what to do with](https://www.linkedin.com/posts/andreychuk_we-have-more-pharma-content-than-we-know-activity-7519351127524556800-3-Qa)
- [Personalisation is one of the biggest lies in marketing](https://www.linkedin.com/posts/andreychuk_personalisation-is-the-biggest-lie-brands-activity-7518922593551392768-eJyw)
- [Pharma saves lives. So why does it still struggle to earn public trust?](https://www.linkedin.com/posts/andreychuk_pharma-saves-lives-so-why-does-it-still-activity-7518963641036193792-9N9K)
- [What a way to kick off NEXT Pharma Summit](https://www.linkedin.com/posts/andreychuk_what-a-way-to-kick-off-next-pharma-summit-activity-7520883835140583424-ATct)

## Brand relationships

- **Viseven** (employment)
- **Pharma Talks** (mention)
- **NEXT Pharma Summit** (mention)
- **Allan Lloyds** (mention)
- **pharmaphorum** (mention)

## Partnerships

The reviewed posts document no partnership or sponsorship offer, so no formats are listed here. What they do show is Nataliya Andreychuk speaking at and reporting from industry events, hosting the Pharma Talks podcast with guests such as Raphael Blum and Rasmus Kalms, and presenting the products of the company she represents — eVa AI, eWizard, and the State of Pharma Content Supply Chain 2026 report. Those are her own commercial activities and employer products, not a published menu a brand can buy into, and the material contains no sponsor policy, deliverables list, pricing, or named inquiry route. For the webinar brief, treat partnership terms as an open question: ask directly about available format, what she would deliver, who handles production and compliance review, and how compensation is handled before building the plan around her. This is an absence of documentation in the material reviewed, not evidence that she declines sponsorship work.

## Alternatives

- Olivier Chateau: Choose Olivier Chateau if the webinar buyer wants the session to move from internal content supply chain mechanics toward the patient-facing side of pharma advertising: DTC regulation, truth in advertising, transparency, and how patient communities already set the standard for honest treatment information. Chateau's posts cover the FDA Commissioner's DTC National remarks — pharma TV ads are protected under the First Amendment, but the FDA sent more than 150 warning letters on misleading drug ads in one year, up from zero in 2024, and the agency wants to replace the current adequate-provision rule with critical information placed in the ad itself. Chateau also led a DTC National session on reimagining consumer engagement through innovation and transparency, and writes from 15+ years building patient communities in digital health. That gives the organiser a speaker who can debate the new rules of engagement for DTC media strategy with firsthand patient-community context.
- Gini Dietrich: Choose Gini Dietrich if the buyer wants a communications-strategy framework applied to pharma campaign activation rather than a content-operations walkthrough. Dietrich's posts use the PESO Model to diagnose why a well-liked pharma ad failed to drive action: the Novartis Super Bowl ad was remembered and won the Pharma Lions Grand Prix at Cannes, but the quiz, locator, clinical guidance, website and email list did not connect, and it ranked 75th for what viewers actually did next. Dietrich also gives a paid media decision rule — only put budget behind a message when it is clear in one sentence, backed by social proof, has an owned destination answering obvious questions, and has already shown signal in shared media. For a webinar on activation, that is a ready-made argument for treating paid, earned, shared and owned as one system, and for not using paid media to manufacture trust.
- Matthew Vignieri: Choose Matthew Vignieri if the buyer wants the webinar to focus on AI readiness for paid media teams and the foundations that must exist before agentic AI is useful. Vignieri's posts draw on a Skai survey of 332 paid media practitioners: teams are far more confident in their people than in the data, systems and operating models that AI agents depend on, and the biggest obstacles are asset readiness, systems and interoperability, and operating model. The posts set out five priorities for making an organisation ready to get the most from AI. For a pharma marketing technology company, that gives a data-backed frame for the argument that AI in content and campaign work depends on structure, governance and workflow — close to the content supply chain activation problem, but arrived at from the media team's readiness side.

---
AI-assisted summary of public posts. Audience demographics are not available. Engagement appears only where we checked recent posts. Method: https://b2binfluencer.marketing/methodology/